Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK3326595 |
Synonyms | |
Therapy Description |
GSK3326595 inhibits PRMT5, potentially resulting in decreased SmD3 methylation and reduced tumor growth (PMID: 28067760, PMID: 25915199, PMID: 32641491). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK3326595 | EPZ015938|GSK 3326595|GSK-3326595 | PRMT5 Inhibitor 17 | GSK3326595 inhibits PRMT5, potentially resulting in decreased SmD3 methylation and reduced tumor growth (PMID: 28067760, PMID: 25915199, PMID: 32641491). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT03614728 | Phase I | Azacitidine + GSK3326595 GSK3326595 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | 0 |